A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004.

This report summarizes the discussions of the International Society of Nephrology (ISN) 2004 Consensus Workshop on Prevention of Progression of Renal Disease, which was held in Hong Kong on June 29, 2004. Three key areas were discussed during the workshop: (1) screening for chronic kidney disease; (2) evaluation and estimating progression of chronic kidney disease; and (3) measures to prevent the progression of chronic kidney disease. Fifteen consensus statements were made in these three areas, as endorsed by the participants of the workshop. The ISN can make use of and take reference to these statements in formulating its policy for tackling chronic kidney disease, a disease with significant global impact.

[1]  B. Kasiske,et al.  K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease , 2003 .

[2]  T. Hostetter.  Prevention of the development and progression of renal disease. , 2003, Journal of the American Society of Nephrology : JASN.

[3]  S. Priori,et al.  2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension , 2003, Heart Drug.

[4]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[5]  A. Levey.  Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  J. Rossert,et al.  Anemia management and the delay of chronic renal failure progression. , 2003, Journal of the American Society of Nephrology : JASN.

[7]  L. Hutchison,et al.  BONE METABOLISM AND DISEASE IN CHRONIC KIDNEY DISEASE , 2007 .

[8]  M. Davidson,et al.  Relationship between dipstick positive proteinuria and albumin:creatinine ratios. , 1999, Journal of diabetes and its complications.

[9]  T A Louis,et al.  A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  The Gisen Group.  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy , 1997, The Lancet.

[11]  B. Kasiske,et al.  Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. , 1997, Kidney international. Supplement.

[12]  A. Garg,et al.  Albuminuria and renal insufficiency prevalence guides population screening: Results from the NHANES III , 2002 .

[13]  G. Beck,et al.  The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .

[14]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[15]  N. Powe,et al.  Screening for proteinuria in US adults: a cost-effectiveness analysis. , 2003, JAMA.

[16]  A. Kitabchi,et al.  Hyperglycemic crises in patients with diabetes mellitus. , 2003, Diabetes care.

[17]  G. Eknoyan,et al.  Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  F. Port,et al.  Risk factors for proteinuria in a large, multiracial, southeast Asian population. , 2002, Journal of the American Society of Nephrology : JASN.

[19]  C. Schmid,et al.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. , 2001, Annals of internal medicine.

[20]  B. C. Kwan,et al.  Prevalence of silent kidney disease in Hong Kong: the screening for Hong Kong Asymptomatic Renal Population and Evaluation (SHARE) program. , 2005, Kidney international. Supplement.

[21]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[22]  G. Eknoyan,et al.  On the evolving nature of understanding dialysis-related disorders. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  A. Levey,et al.  Cardiovascular disease and chronic renal disease: a new paradigm. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  M. Dichgans.  CADASIL: A Monogenic Condition Causing Stroke and Subcortical Vascular Dementia , 2002, Cerebrovascular Diseases.

[25]  B. Freedman,et al.  The importance of family history on the development of renal disease , 2004, Current opinion in nephrology and hypertension.

[26]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[27]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[28]  P. Whelton,et al.  End-stage renal disease in African-American and white men. 16-year MRFIT findings. , 1997, JAMA.

[29]  W. McClellan,et al.  Taking a public health approach to the prevention of end-stage renal disease: the NKF Singapore Program. , 2003, Kidney international. Supplement.

[30]  C. Hamilton,et al.  Nonsteroidal Anti‐Inflammatory Drugs: Effects on Kidney Function , 1991, Journal of clinical pharmacology.

[31]  G. Eknoyan,et al.  National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.

[32]  W. Mitch,et al.  Diets for patients with chronic kidney disease, still worth prescribing. , 2004, Journal of the American Society of Nephrology : JASN.

[33]  W. Mitch,et al.  The precision of estimating protein intake of patients with chronic renal failure. , 2002, Kidney international.

[34]  S. Klahr,et al.  Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. , 1987, Archives of internal medicine.

[35]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  D. Rogers,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus , 1994 .

[37]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[38]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[39]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[40]  A. Garg,et al.  Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. , 2003, Kidney international.

[41]  David W Dunstan,et al.  Prevalence of kidney damage in Australian adults: The AusDiab kidney study. , 2003, Journal of the American Society of Nephrology : JASN.

[42]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[43]  B. Kasiske,et al.  K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease , 2003 .

[44]  B. Freedman,et al.  Family history of end-stage renal disease among incident dialysis patients. , 1997, Journal of the American Society of Nephrology : JASN.

[45]  Bruce Kupelnick,et al.  K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease , 2004 .

[46]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[47]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[48]  B. Pereira,et al.  Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[49]  J. Coresh,et al.  Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. , 2003, Kidney international.

[50]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[51]  K. Iseki,et al.  Risk of developing end-stage renal disease in a cohort of mass screening. , 1996, Kidney international.

[52]  Mark E Molitch,et al.  Nephropathy in diabetes. , 2004, Diabetes care.

[53]  J P Kriss,et al.  Limitations of creatinine as a filtration marker in glomerulopathic patients. , 1985, Kidney international.

[54]  M. Rudnick,et al.  Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism--a critical review. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[55]  M. Pfeffer,et al.  Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[56]  Ruddle Fh,et al.  Human gene mapping 3. Baltimore Conference (1975). Third International Workshop on Human Gene Mapping. Report of the committee on the genetic constitution of autosomes other than chromosomes 1, 2, and 6. , 1976, Cytogenetics and cell genetics.

[57]  Michael J Lysaght,et al.  Maintenance dialysis population dynamics: current trends and long-term implications. , 2002, Journal of the American Society of Nephrology : JASN.

[58]  Tom Greene,et al.  Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[59]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[60]  Lysaght Mj,et al.  Maintenance Dialysis Population Dynamics: Current Trends and Long-Term Implications , 2002 .

[61]  G. Beck,et al.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. , 1994, The New England journal of medicine.

[62]  D. Grobbee,et al.  Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity , 2001, Journal of internal medicine.